Select your language
EN
FR
Home
About
About
Abionyx
Management
Board of Directors
Specialized Committees
- Audit Committee
- Remuneration Committee
Scientific Advisory Board
Our Assets
Our Assets
CER 001
CER 002
CER 209
Indications
LCAT
Sepsis
COVID
Media
Media
Press releases
ABIONYX in the media
Investors
Investors
Regulated information
Shareholder meeting
Analyst Research
Abionyx on stock market
Investor Contacts
Financial Calendar
Media
Press releases
ABIONYX in the media
ABIONYX Pharma announces positive preclinical results in a model of uveitis and launches the strategic development of the first class of biomedicines in ophthalmology based on its bio-HDL
Fichier:
abionyx_pr_100721_0a035.pdf